CONSHOHOCKEN, Pa., July 7 — TJP, an agency specializing in strategic, creative, and digital solutions for patient and market access teams as well as consumer brands, and portfolio company of Renovus Capital Partners, today announced its add-on of FX2 Virtual. FX2 Virtual is a specialized life sciences commercial operations agency led by pharmaceutical industry veterans Ed Kessig, Jeff Cino and Sal Paolozza that provides high-impact virtual sales professionals, patient access reimbursement support, and advanced omnichannel data analytics.
The addition of FX2 Virtual enables TJP to expand its life sciences capabilities from market and patient access strategy, patient journey design, and digital execution into virtual commercial deployment and field-level execution. Through FX2 Virtual’s operational infrastructure, the combined entity now delivers specialized Virtual Sales Organizations and Virtual Key Account Managers (vKAMs) alongside its analytical data management, CRM optimization, and incentive compensation capabilities.
“Bringing FX2 Virtual into the fold marks a pivotal evolution for TJP, allowing us to connect strategic insight with real-world, commercial pull-through,” said Rino Mariconda, CEO of TJP. “Historically, we have excelled at designing the strategy-led creative, field enablement tools, and access intelligence that brands need to succeed. By adding a dedicated virtual sales force, virtual key account management team and data/analytics, we can now directly drive the execution of that strategy, ensuring our life sciences partners achieve stronger adoption and pull-through in the market.”
Following the combination, FX2 Virtual will operate as a standalone brand under the TJP corporate umbrella, fully integrating its virtual commercial and analytical assets into TJP’s core service offerings. The FX2 Virtual team will work alongside TJP’s strategic and creative leaders to offer clients a single, unified partner capable of navigating complex access barriers while actively deploying field-level solutions.
“We are thrilled to join forces with TJP and Renovus Capital to close the loop between access strategy and field execution,” said Ed Kessig, Founding Partner FX2 Virtual. “Aligning our Virtual Sales Organizations and vKAM capabilities with TJP’s expertise allows us to apply our skills where they matter most—not just explaining the access pathway, but actively driving the brand adoption and ensuring patients receive the medicines they ultimately need.”
The combined offerings perfectly complement one another by bridging the gap between strategy, tactical development, human pull-through and analytics/measurement. While TJP provides the essential strategic foundation, value story harmonization, and tactical development, FX2 Virtual delivers the tactical sales teams and advanced operations analytics necessary to build, deploy, and maintain high-performing virtual field teams that maximize brand ROI and improve patient outcomes in the real world.